• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc. (Amendment)

    5/13/24 8:40:34 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLUE alert in real time by email
    SC 13D/A 1 nea17-monterosa_18840.htm NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Monte Rosa Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    61225M102

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600

    Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    May 9, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 61225M102

    13D Page 2 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 17, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 61225M102

    13D Page 3 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 17, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     CUSIP No. 61225M102

    13D Page 4 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 17 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 5 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 6 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Ali Behbahani

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    82,632 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    82,632 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,784,930 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 7 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Carmen Chang

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 8 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 9 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 10 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Edward T. Mathers

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 11 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 12 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Paul Walker

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

      

    CUSIP No. 61225M102

    13D Page 13 of 23 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Rick Yang

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    7,692,298 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    7,692,298 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,692,298 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    15.2%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 61225M102

    13D Page 14 of 23 Pages    

     

    Item 1. Security and Issuer.

    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D originally filed on July 12, 2021, and relates to the common stock, $0.0001 par value per share (“Common Stock”), of Monte Rosa Therapeutics, Inc. (the “Issuer”), having its principal executive office at 321 Harrison Avenue, Suite 900, Boston, MA 02118.

     

    Certain terms used but not defined in this Amendment No. 1 have the meaning assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

    This Amendment No. 1 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding. 

     

     

    Item 2. Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 17, L.P. (“NEA 17”); NEA Partners 17, L.P. (“NEA Partners 17”), which is the sole general partner of NEA 17; and NEA 17 GP, LLC (“NEA 17 LLC” and, together with NEA Partners 17, the “Control Entities”), which is the sole general partner of NEA Partners 17; and

     

    (b) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Edward T. Mathers (“Mathers”), Scott D. Sandell (“Sandell”), Paul Walker (“Walker”) and Rick Yang (“Yang”) (together, the “Managers”) and Liza Landsman (“Landsman”), Joshua Makower (“Makower”) and Peter W. Sonsini (“Sonsini”). The Managers are the managers of NEA 17 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 17, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Behbahani, Baskett, Chang, Makhzoumi, Walker and Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence and Mathers is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 17 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 17 is to act as the sole general partner of NEA 17. The principal business of NEA 17 LLC is to act as the sole general partner of NEA Partners 17. The principal business of each of the Managers is to manage the Control Entities and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 17 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 17 and NEA Partners 17 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen. 

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

    Not applicable.

     

     

     

    Item 4. Purpose of Transaction.

    Not applicable.

     

     

     

    CUSIP No. 61225M102

    13D Page 15 of 23 Pages    

     

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)NEA 17 is the record owner of the NEA 17 Shares. As the general partner of NEA 17, NEA Partners 17 may be deemed to own beneficially the NEA 17 Shares. As the sole general partner of NEA Partners 17, NEA 17 LLC may be deemed to own beneficially the NEA 17 Shares. As members of NEA 17 LLC, each of the Managers may be deemed to own beneficially the NEA 17 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 17 Shares other than those shares which such person owns of record.

     

    As of May 13, 2024, Behbahani is the record owner of options to purchase 82,632 shares of Common Stock (the “Behbahani Option Shares”), exercisable within 60 days.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on the 50,512,019 shares of Common Stock reported by the Issuer to be outstanding as of May 6, 2024 on the Issuer’s Form 10-Q filed with the SEC on May 9, 2024. The percentage set forth on the cover sheet for Behbahani is calculated based on the shares described in the preceding sentence plus the Behbahani Option Shares.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)On June 23, 2021, Behbahani was granted a stock option to purchase 47,132 shares of Common Stock at $19 per share for his service as a member of the Board of Directors of the Issuer. The shares subject to this option vest and become exercisable in 36 equal installments which began June 28, 2021. The remaining 1,310 shares subject to this option are expected to vest and become exercisable in full by March 28, 2024, subject to Behbahani’s continued service on such vesting date.

     

    On June 14, 2023, Behbahani was granted a stock option to purchase 20,500 shares of Common Stock at $6.59 per share for his services as a member of the Board of Directors of the Issuer. The shares of this option are expected to vest and become exercisable in full on June 14, 2024, subject to Behbahani’s continued service on such vesting date.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)Each of Landsman, Makower and Sonsini has ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock as a result of ceasing to be a manager of NEA 16 LLC.

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

     

    Item 7. Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

    Exhibit 3 – Power of Attorney on behalf of Liza Landsman regarding filings under the Securities Exchange Act of 1934, as amended.

    Exhibit 4 – Power of Attorney on behalf of Joshua Makower regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

    CUSIP No. 61225M102

    13D Page 16 of 23 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 13th day of May, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 17, L.P.

     

    By:

    NEA PARTNERS 17, L.P.

    General Partner

     

    By:

    NEA 17 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

     

    NEA PARTNERS 17, L.P.

     

    By:NEA 17 GP, LLC
    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

     

      

    NEA 17 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

    CUSIP No. 61225M102

    13D Page 17 of 23 Pages    

     

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Liza Landsman

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Edward T. Mathers

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker

     

     

                     *                        

    Rick Yang

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2, Exhibit 3, and Exhibit 4.

     

     

     
     

     

    CUSIP No. 61225M102

    13D Page 18 of 23 Pages    

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Monte Rosa Therapeutics, Inc.

     

    EXECUTED this 13th day of May, 2024.

     

     

     

    NEW ENTERPRISE ASSOCIATES 17, L.P.

     

    By:

    NEA PARTNERS 17, L.P.

    General Partner

     

    By:

    NEA 17 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

     

    NEA PARTNERS 17, L.P.

     

    By:NEA 17 GP, LLC
    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer  

     

      

    NEA 17 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

     

    CUSIP No. 61225M102

    13D Page 19 of 23 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Liza Landsman

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Edward T. Mathers

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker

     

     

                     *                        

    Rick Yang

     

     

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

    This Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2, Exhibit 3, and Exhibit 4.

     

     

     

    CUSIP No. 61225M102

    13D Page 20 of 23 Pages    

    EXHIBIT 2

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

     

     

     

    CUSIP No. 61225M102

    13D Page 21 of 23 Pages    

     

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     

     

     

     

    CUSIP No. 61225M102

    13D Page 22 of 22 Pages    

     

    EXHIBIT 3

       

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 1st day of May, 2024.

     

     

     

    /s/ Liza Landsman  
    Liza Landsman  

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 61225M102

    13D Page 23 of 22 Pages    

     

    EXHIBIT 4

       

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager or former general partner, director, officer or manager of any New Enterprise Associates partnership, corporation or limited liability company, solely with respect to the following entities: Black Diamond Therapeutics, Inc., Inventiva S.A., Marker Therapeutics, Monte Rosa Therapeutics, Inc., and Reneo Pharmaceuticals, Inc. (the “Covered Entities”), pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney will last for the duration of the outstanding filing obligations related to the undersigned and NEA Management Company, LLC, and its affiliates. Upon the removal of the undersigned from all outstanding Form 3, 4, and 5, Schedule 13D and 13G or any other similarly related obligatory filings related to the Covered Entities, the power provided herein shall be revoked.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 2nd day of May, 2024.

     

     

     

    /s/ Joshua Makower  
    Joshua Makower  

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

     

    Get the next $GLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLUE

    DatePrice TargetRatingAnalyst
    12/19/2024$14.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    2/15/2024$11.00Outperform
    Wedbush
    1/3/2023$18.00Equal Weight → Overweight
    Wells Fargo
    10/13/2022$22.00Buy
    UBS
    8/15/2022$20.00Buy
    Jefferies
    4/28/2022$19.00Neutral
    Credit Suisse
    2/10/2022$19.00Equal-Weight
    Wells Fargo
    10/14/2021$20.00Mkt Perform
    SVB Leerink
    More analyst ratings

    $GLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

      SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      11/14/24 1:22:39 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

      SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      11/12/24 10:32:12 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc.

      SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      10/30/24 5:10:55 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

      VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clin

      5/8/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

      CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue

      4/28/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

      Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr

      3/20/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      3/25/25 6:32:00 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

      BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea

      12/13/24 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

      BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of

      7/26/23 7:30:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

      BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon

      3/23/23 7:30:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Financials

    Live finance-specific insights

    See more
    • Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

      Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr

      3/20/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

      Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for 

      3/11/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

      Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.m. ET today BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including l

      10/17/23 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.

      10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      5/8/25 7:14:15 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      5/8/25 7:11:22 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Monte Rosa Therapeutics Inc.

      DEFA14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      4/25/25 4:02:35 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Monte Rosa Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Monte Rosa Therapeutics from Overweight to Equal Weight and set a new price target of $11.00 from $14.00 previously

      12/19/24 7:39:47 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

      Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00

      2/15/24 6:27:11 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00

      1/3/23 8:03:46 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      3/25/25 6:32:00 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Business & Legal Officer Nickson Philip was granted 36,000 shares (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      1/6/25 4:15:17 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Principal Accounting Officer Dunn Edmund was granted 11,850 shares, increasing direct ownership by 85% to 25,794 units (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      1/6/25 4:15:13 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care